Halozyme Therapeutics | HALO - Betriebsergebnis





Betriebsergebnis Veränderung Datum
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Amarin USD -2.26M 564K 2025-12
Amgen USD 4.61B 777M 2026-06
Baxter International USD 276M 210M 2026-06
Cara Therapeutics USD -7.05M 1.11M 2026-03
Cytokinetics USD -179.17M 2.05M 2026-06
DBV Technologies USD -47.9M 2.85M 2026-03
Eli Lilly USD 12.46B 2.68B 2026-06
Halozyme Therapeutics USD -63.72M 1.95M 2026-06
Intrexon USD -60.84M 26.62M 2024-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
MannKind USD -68.23M 8.76M 2026-06
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Pfizer USD 667M 4.32B 2026-06
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
United Therapeutics USD 330.8M 5M 2026-06
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12